Protection of Adenovirus from Neutralizing Antibody by Cationic PEG Derivative Ionically Linked to Adenovirus

Overview

Journal Int J Nanomedicine

Publisher Dove Medical Press

Specialty Biotechnology

Date 2012 Mar 14

PMID 22412299

Citations 15

Authors

Qin Zeng

Jianfeng Han

Dong Zhao

Tao Gong

Zhirong Zhang

Xun Sun

Affiliations

Soon will be listed here.

Abstract

Background: The generation of anti-adenovirus neutralizing antibody (NAb) in humans severely restricts the utilization of recombinant adenovirus serotype 5 (Ad5) vectors in gene therapy for a wide range of clinical trials. To overcome this limitation, we ionically complexed Ad5 with a newly synthesized copolymer, which we called APC, making an adenovirus shielded from NAb.

Methods: APC, a cationic polyethylene glycol derivative, was synthesized via two steps of ring-opening copolymerization of ethylene oxide and allyl glycidyl ether, followed by the addition of 2-mercaptoethylamine. The copolymer or the control PEI-2k was ionically complexed to anionic Ad5 in 5% glucose, and in vitro transduction assays were carried out in coxsackievirus and adenovirus receptor-positive cells (A549) and coxsackievirus and adenovirus receptor-negative cells (B16 and SKOV3). The physical properties and morphology of adenovirus alone or the complexes were investigated respectively by zeta potential, size distribution, and transmission electron microscopy image. Then cytotoxicity of APC was examined using 3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide assays. Finally, the ability of APC to protect adenovirus from NAb was evaluated by transfection assays after a neutralizing effect.

Results: APC was successfully synthesized and showed a low cytotoxicity. Positively charged Ad5/APC exhibited slightly increased diameter (130.2 ± 0.60 nm) than naked Ad5 (115.6 ± 5.46 nm) while Ad5/PEI-2k showed severe aggregation (1382 ± 79.9 nm). Ad5/APC achieved a gene transfection level as high as Ad5/PEI-2k in A549 or B16 cells, and significantly higher than Ad5/PEI-2k in SKOV3 cells. Most importantly, after the exposure to the neutralizing antibody, naked Ad5 and Ad5/PEI-2k exhibited poor gene expression while Ad5/APC still showed significantly efficient gene expression.

Conclusion: Our results demonstrated that Ad5/APC complex offered good protection for Ad5 against NAb in vitro and suggested a potential strategy of resistance to NAb in vivo.

Citing Articles

The Immune System-A Double-Edged Sword for Adenovirus-Based Therapies.

Wallace R, Bliss C, Parker A Viruses. 2024; 16(6).

PMID: 38932265 PMC: 11209478. DOI: 10.3390/v16060973.

Lung-Targeted Transgene Expression of Nanocomplexed Ad5 Enhances Immune Response in the Presence of Preexisting Immunity.

Yang Y, Wu S, Wang Y, Shao F, Lv P, Li R Engineering (Beijing). 2023; .

PMID: 36714358 PMC: 9869631. DOI: 10.1016/j.eng.2022.12.007.

Effects of pre-existing anti-adenovirus antibodies on transgene expression levels and therapeutic efficacies of arming oncolytic adenovirus.

Ono R, Nishimae F, Wakida T, Sakurai F, Mizuguchi H Sci Rep. 2022; 12(1):21560.

PMID: 36513733 PMC: 9747716. DOI: 10.1038/s41598-022-26030-3.

Oligopeptide-modified poly(beta-amino ester)s-coated AdNuPARmE1A: Boosting the efficacy of intravenously administered therapeutic adenoviruses.

Brugada-Vila P, Cascante A, Lazaro M, Castells-Sala C, Fornaguera C, Rovira-Rigau M Theranostics. 2020; 10(6):2744-2758.

PMID: 32194832 PMC: 7052890. DOI: 10.7150/thno.40902.

Oncolytic Viruses and the Immune System: The Dynamic Duo.

de Matos A, Franco L, McFadden G Mol Ther Methods Clin Dev. 2020; 17:349-358.

PMID: 32071927 PMC: 7015832. DOI: 10.1016/j.omtm.2020.01.001.

References

Hofherr S, Mok H, Gushiken F, Lopez J, Barry M . Polyethylene glycol modification of adenovirus reduces platelet activation, endothelial cell activation, and thrombocytopenia. Hum Gene Ther. 2007; 18(9):837-48. DOI: 10.1089/hum.2007.0051. View

Morral N, ONeal W, Rice K, Leland M, Piedra P, Aguilar-Cordova E . Lethal toxicity, severe endothelial injury, and a threshold effect with high doses of an adenoviral vector in baboons. Hum Gene Ther. 2002; 13(1):143-54. DOI: 10.1089/10430340152712692. View

Fisher K, Green N, Hale A, Subr V, Ulbrich K, Seymour L . Passive tumour targeting of polymer-coated adenovirus for cancer gene therapy. J Drug Target. 2007; 15(7-8):546-51. DOI: 10.1080/10611860701501014. View

Matthews Q . Capsid-incorporation of antigens into adenovirus capsid proteins for a vaccine approach. Mol Pharm. 2010; 8(1):3-11. PMC: 3034826. DOI: 10.1021/mp100214b. View

Meier O, Greber U . Adenovirus endocytosis. J Gene Med. 2004; 6 Suppl 1:S152-63. DOI: 10.1002/jgm.553. View

Eto Y, Yoshioka Y, Mukai Y, Okada N, Nakagawa S . Development of PEGylated adenovirus vector with targeting ligand. Int J Pharm. 2007; 354(1-2):3-8. DOI: 10.1016/j.ijpharm.2007.08.025. View

Croyle M, Chirmule N, Zhang Y, Wilson J . "Stealth" adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung. J Virol. 2001; 75(10):4792-801. PMC: 114234. DOI: 10.1128/JVI.75.10.4792-4801.2001. View

Haisma H, Bellu A . Pharmacological interventions for improving adenovirus usage in gene therapy. Mol Pharm. 2010; 8(1):50-5. DOI: 10.1021/mp100310h. View

Wang I, Jhuang M, Chen Y, Yeh L, Liu C, Young T . Chitosan modification of adenovirus to modify transfection efficiency in bovine corneal epithelial cells. PLoS One. 2010; 5(8):e12085. PMC: 2919409. DOI: 10.1371/journal.pone.0012085. View

10.

Wu T, Ertl H . Immune barriers to successful gene therapy. Trends Mol Med. 2008; 15(1):32-9. DOI: 10.1016/j.molmed.2008.11.005. View

11.

Han J, Zhao D, Zhong Z, Zhang Z, Gong T, Sun X . Combination of adenovirus and cross-linked low molecular weight PEI improves efficiency of gene transduction. Nanotechnology. 2010; 21(10):105106. DOI: 10.1088/0957-4484/21/10/105106. View

12.

Zaiss A, Machado H, Herschman H . The influence of innate and pre-existing immunity on adenovirus therapy. J Cell Biochem. 2009; 108(4):778-90. PMC: 2822460. DOI: 10.1002/jcb.22328. View

13.

Davis H, Morgan J, Yarmush M . Polybrene increases retrovirus gene transfer efficiency by enhancing receptor-independent virus adsorption on target cell membranes. Biophys Chem. 2002; 97(2-3):159-72. DOI: 10.1016/s0301-4622(02)00057-1. View

14.

Park J, Mok H, Park T . Physical adsorption of PEG grafted and blocked poly-L-lysine copolymers on adenovirus surface for enhanced gene transduction. J Control Release. 2009; 142(2):238-44. DOI: 10.1016/j.jconrel.2009.11.001. View

15.

Eto Y, Gao J, Sekiguchi F, Kurachi S, Katayama K, Maeda M . PEGylated adenovirus vectors containing RGD peptides on the tip of PEG show high transduction efficiency and antibody evasion ability. J Gene Med. 2004; 7(5):604-12. DOI: 10.1002/jgm.699. View

16.

Kelkar S, Pfister K, Crystal R, Leopold P . Cytoplasmic dynein mediates adenovirus binding to microtubules. J Virol. 2004; 78(18):10122-32. PMC: 515014. DOI: 10.1128/JVI.78.18.10122-10132.2004. View

17.

Ahn C, Chae S, Bae Y, Kim S . Synthesis of biodegradable multi-block copolymers of poly(L-lysine) and poly(ethylene glycol) as a non-viral gene carrier. J Control Release. 2004; 97(3):567-74. DOI: 10.1016/j.jconrel.2004.04.002. View

18.

Hofherr S, Shashkova E, Weaver E, Khare R, Barry M . Modification of adenoviral vectors with polyethylene glycol modulates in vivo tissue tropism and gene expression. Mol Ther. 2008; 16(7):1276-82. DOI: 10.1038/mt.2008.86. View

19.

Singh R, Kostarelos K . Designer adenoviruses for nanomedicine and nanodiagnostics. Trends Biotechnol. 2009; 27(4):220-9. DOI: 10.1016/j.tibtech.2009.01.003. View

20.

Kim J, Lee S, Cho Y, Choi J, Kim Y, Lee J . Enhancement of the adenoviral sensitivity of human ovarian cancer cells by transient expression of coxsackievirus and adenovirus receptor (CAR). Gynecol Oncol. 2002; 85(2):260-5. DOI: 10.1006/gyno.2002.6607. View